| 4.13 0.68 (19.71%) | 05-14 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.03 |
1-year : | 5.87 |
| Resists | First : | 4.3 |
Second : | 5.03 |
| Pivot price | 3.17 |
|||
| Supports | First : | 3.4 |
Second : | 2.84 |
| MAs | MA(5) : | 3.38 |
MA(20) : | 3.23 |
| MA(100) : | 2.44 |
MA(250) : | 1.91 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 49.9 |
| RSI | RSI(14): 70.6 |
|||
| 52-week | High : | 4.3 | Low : | 1.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MGNX ] has closed Bollinger Bands are 59.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.61 - 3.63 | 3.63 - 3.64 |
| Low: | 3.23 - 3.26 | 3.26 - 3.27 |
| Close: | 3.42 - 3.45 | 3.45 - 3.48 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Wed, 13 May 2026
MacroGenics (MGNX) Reports Strong Q1 Revenue and Strategic Movem - GuruFocus
Wed, 13 May 2026
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 13 May 2026
Is MacroGenics (MGNX) 10.6% Undervalued After Q1 2026 Beat? EPS - GuruFocus
Wed, 13 May 2026
MacroGenics reports Q1 2026 loss of $36.8M; revenue rises to $20.8M, cash runway extended through 2028 - TradingView
Wed, 13 May 2026
MacroGenics: Q1 Earnings Snapshot - KTVB
Tue, 12 May 2026
MacroGenics stock (US5562221046): $122.5M manufacturing sale to Bora marks strategic pivot - AD HOC NEWS
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 64.1 (%) |
| Shares Short | 2,930 (K) |
| Shares Short P.Month | 3,980 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | -50 % |
| Operating Margin | -29.4 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | -87 % |
| Qtrly Rev. Growth | 113 % |
| Gross Profit (p.s.) | -0.53 |
| Sales Per Share | 2.35 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -3.4 |
| PEG Ratio | 0 |
| Price to Book value | 4.55 |
| Price to Sales | 1.7 |
| Price to Cash Flow | -3.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|